A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus

2024-520385-57-01 Protocol TNT119-SLE-101 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 26 Nov 2025 · Status Ongoing, recruiting · 4 EU/EEA countries · 8 sites · Protocol TNT119-SLE-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 24
Countries 4
Sites 8

Systemic Lupus Erythematosus

Key facts

Sponsor
Climb Bio Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
26 Nov 2025 → ongoing
Decision date (initial)
2025-11-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Systemic Lupus Erythematosus

VersionLevelCodeTermSystem organ class
21.1 PT 10042945 Systemic lupus erythematosus 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Climb Bio Inc.

Sponsor organisation
Climb Bio Inc.
Address
20 William Street Suite 145
City
Wellesley Hills
Postcode
02481-4124
Country
United States

Scientific contact point

Organisation
Climb Bio Inc.
Contact name
Janaki Subramanyam

Public contact point

Organisation
Climb Bio Inc.
Contact name
Janaki Subramanyam

Locations

4 EU/EEA countries · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ongoing, recruiting 3 2
Greece Authorised, recruiting 3 3
Romania Ongoing, recruiting 2 1
Spain Ongoing, recruiting 3 2
Rest of world
Ukraine, United States, Georgia
13

Investigational sites

Bulgaria

2 sites · Ongoing, recruiting
Multispecialty hospital for active treatment Sveta Sofia EOOD
Department of Internal Diseases, Bulevard Bilgariya 104, 1404, Sofiya
University Multiprofile Hospital For Active Treatment Saint Georgi EAD
Clinic of Rheumatology,, Bulevard Vasil Aprilov 15a, 4002, Plovdiv

Greece

3 sites · Authorised, recruiting
Geniko Nosokomeio Thessalonikis George Papanikolaou
Nephrology Department, Exochi, 570 10, Thessaloniki
Ippokratio General Hospital Of Thessaloniki
Nephrology Department, Konstadinoupoleos 49, 546 42, Thessaloniki
Laiko General Hospital Of Athens
A’ Department of Propaeudeutic Internal Medicine, Agiou Thoma (goudi) 17, 115 27, Athens

Romania

1 site · Ongoing, recruiting
Spitalul Clinic Judetean De Urgenta Cluj
Medical II, Strada Clinicilor 3-5, 400006, Cluj-Napoca

Spain

2 sites · Ongoing, recruiting
Complexo Hospitalario Universitario A Coruna
Rheumatology Service, Lugar Jubias De Arriba 84, 15006, A Coruna
Parc Tauli Hospital Universitari
Rheumatology Service, Parc Del Tauli 1, 08208, Sabadell

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2025-11-28 2025-12-11
Greece 2026-02-02
Romania 2025-11-26 2025-12-15
Spain 2025-12-11 2026-05-21

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-07-28 Spain Acceptable
2025-10-29
2025-10-31
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-08 Acceptable
2025-10-29
2025-12-08
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-19 Acceptable
2025-10-29
2025-12-19
4 NON SUBSTANTIAL MODIFICATION NSM-3 2026-01-29 Spain Acceptable
2025-10-29
2026-01-29
5 SUBSTANTIAL MODIFICATION SM-1 2026-03-12 Spain Acceptable 2026-04-20
6 SUBSTANTIAL MODIFICATION SM-2 2026-03-16 Acceptable 2026-05-04
7 SUBSTANTIAL MODIFICATION SM-3 2026-03-19 Acceptable 2026-06-02
8 SUBSTANTIAL MODIFICATION SM-4 2026-03-20 Acceptable 2026-04-29